Gwo Xi Stem Cell Applied Technology Co. , Ltd
Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs. Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of … Read more
Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) - Total Liabilities
Latest total liabilities as of June 2025: NT$387.25 Million TWD
Based on the latest financial reports, Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) has total liabilities worth NT$387.25 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Gwo Xi Stem Cell Applied Technology Co. , Ltd - Total Liabilities Trend (2019–2024)
This chart illustrates how Gwo Xi Stem Cell Applied Technology Co. , Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Gwo Xi Stem Cell Applied Technology Co. , Ltd Competitors by Total Liabilities
The table below lists competitors of Gwo Xi Stem Cell Applied Technology Co. , Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
India Nippon Electricals Limited
NSE:INDNIPPON
|
India | ₹2.41 Billion |
|
Spigen Korea Co. Ltd
KQ:192440
|
Korea | ₩56.34 Billion |
|
Peak Minerals Ltd
AU:PUA
|
Australia | AU$382.38K |
|
AirBoss of America Corp
OTCQX:ABSSF
|
USA | $186.97 Million |
|
Edda Wind ASA
OL:EWIND
|
Norway | Nkr395.75 Million |
|
Frasers Property (Thailand) Public Company Limited
BK:FPT
|
Thailand | ฿57.14 Billion |
|
Emporiki Eisagogiki Aftokiniton Ditrohon kai Mihanon Thalassis Societe Anonyme
AT:MOTO
|
Greece | €54.21 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Gwo Xi Stem Cell Applied Technology Co. , Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gwo Xi Stem Cell Applied Technology Co. , Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gwo Xi Stem Cell Applied Technology Co. , Ltd (2019–2024)
The table below shows the annual total liabilities of Gwo Xi Stem Cell Applied Technology Co. , Ltd from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$400.79 Million | -16.76% |
| 2023-12-31 | NT$481.49 Million | -9.93% |
| 2022-12-31 | NT$534.57 Million | -10.25% |
| 2021-12-31 | NT$595.65 Million | +3.14% |
| 2020-12-31 | NT$577.51 Million | +23.89% |
| 2019-12-31 | NT$466.14 Million | -- |